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Abstract It is widely acknowledged that compliance and
persistence with oral osteoporosis medications, particularly
with bisphosphonates, is poor. Several excellent reviews have
been written on compliance and persistence with osteoporosis
medications and have discussed improvements seen with
extended dosing intervals. This review begins with studies on
extended dosing intervals to examine the limitations of
administrative claims data. It also looks at compliance and
persistence across multiple medical conditions, examining the
importance of prescription fulfillment, intentional choice,
causation and possible interventions.
Keywords Osteoporosis.Persistence.Compliance.
Adherence
1 The negative consequences of poor adherence
Using claims databases several authors have found an
association between compliance and persistence with
osteoporosis medication and fracture risk reduction. Siris
in 2006 [1] examined the relationship of persistence and
medical possession ratio (MPR) to fracture rate of vertebral
and nonvertebral fractures. Total vertebral, nonvertebral and
hip fractures were significantly lower in compliant and
persistent patients with relative risk reductions of 20–45%.
Huybrechts [2] studied the relationship between compliance
as measured by medication possession ratio (MPR) and
fracture rate in a US managed care database. Low
compliance as measured by a MPR of <80% was associated
with a 17% increase in fracture rate, adjusting for other
known risk factors. Low compliance was also associated
with a 37% increase in risk of all cause hospitalization and
average monthly costs of all medical services were higher.
Rabenda [3] used the Belgian national security database to
study the relationship of MPR to hip fracture risk. For each
decrease of 1% in MPR, the risk of hip fracture increased
by 0.4%. The relative risk reduction at 12 months for hip
fracture was 60% for persistent compared to nonpersistent
patients.
2 Adherence and risk of fracture: is there a healthy
adherer bias?
The positive effects of adherence on fracture risk reduction
noted above may also arise from what has been termed
“healthy adherer bias”. Adherence maybe a marker for
adherence to effective treatments other than study medi-
cations or to other adherence behaviors that effect out-
comes. Granger [4] in the CHARM trial found that good
adherence was associated with lower all cause mortality in
both treatments and placebo arms. If patients who adhere to
osteoporosis pharmacologic therapies are more likely to
take calcium, vitamin D, and engage in physical activity,
for example, then the projected effects of calcium, vitamin
D, and physical activity maybe falsely attributed to the
pharmacologic therapy. However, there have been no
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bias in explaining survival after acute myocardial infarction
with adherence to medications improving mortality benefits
such as statins and beta-blockers but no calcium channel
blockers being associated with increased survival [5].
However, these data are limited in that they refer to
secondary prevention rather than primary prevention.
Secondary prevention indicates a negative health event,
such as heart attack or fracture, has occurred prior to
patients adhering to therapy after a cardiac event or
fracture. In such cases, the event may drive patients to
engage in protective behaviors to avoid additional future
events. However, it is not likely that healthy adherer bias
will play a major role in osteoporosis. The epidemic of
vitamin D deficiency is illustrated by Holick [6] who
reports that over 50% of postmenopausal women on
osteoporosis therapies do not have adequate vitamin D
levels.
A second type of healthy adherer bias has been pointed
out is that patients who are well adherent to placebo in drug
trials also have significant fracture reduction effect. This
has been pointed out by Curtis [7] in an analysis of
Women’s Health Initiative (WHI). Examining adherence to
medication in the placebo arm of the estrogen/hormone
therapy component of the WHI (n=13,485), Curtis [7]
found that there was a consistent association between
adherence to placebo and protective effect for all outcomes
that was especially strong for hip fracture and death. They
conclude that medication adherence which can be measured
in administrative databases or other secondary data sources
maybe a proxy for other positive health behaviors (e.g.,
adequate calcium and vitamin D intake, exercise) that may
not be available in these databases.
3 Adherence and dosing interval: do longer dosing
intervals improve compliance and persistence?
Data from both administrative claims data and pharmacy
claims data have shown improved persistence and compli-
ance (as measured by medication possession ratio) on oral
bisphosphonate therapy with extended dosing intervals
from daily to weekly. Data on compliance and persistence
with monthly bisphosphonate therapy have been equivocal.
Several studies have shown improved compliance with a
longer dosing interval, while others have not. Several
factors may contribute to these findings: the limitations of
pharmacy claims data which do not allow for correction due
to confounding variables which administrative claims do, or
methodologic definitions of the refill gap (the length of the
time between doses that is allowed to define persistence on
therapy). Monthly ibandronate for example showed im-
proved persistence when the refill gap was measured as
45 days as compared to 30 days, the standard refill gap for
weekly bisphosphonate therapy showed improved persis-
tence [8]. When the refill gap was defined as 30 days for
both, then there was no superiority for monthly ibandro-
nate. Gold and colleagues [9] using pharmacy claims data
and a 90-day refill gap did not find improved persistence
with monthly over weekly therapy. They report that they
used 15, 30, 45, 60, and 90 day refill gaps without finding
any meaningful differences in outcomes.
4 Limitations of claims data
The studies mentioned above which use administrative
claims data have limitations due to the nature of such data.
Claims data do not tell us about samples given to patients
or whether patients fulfill their scripts (primary medication
nonadherence, see below). Claims data provide information
on procedures and visits but may not include key control
variables. For example important variables in any study of
osteoporosis patients are likely to be bone density (DXA)
measurements or calcium intake, but typically this infor-
mation is not available in a claims database. Because DXA
is a procedure, it is possible to determine that the test was
reimbursed but not what its outcomes are. Further, in
observational studies, outcomes can reflect a lack of
comparability between treatment groups rather than the
effects of treatment. Propensity scores show promise in
helping to adjust for such selection bias [10].
5 Compliance with medications
There are multiple studies that have shown poor compli-
ance with dosing instructions with use of oral bisphosph-
onates for the treatment of osteoporosis. Hamilton and
colleagues [11] found that 57/219 patients on risedronate
did not follow instructions properly. Those who stayed
upright after taking the medicine were more likely to have
adverse events and discontinue. Approximately one-third of
patients who experienced adverse events were rechallenged
with the drug, and almost 50% were able to restart. This
study makes clear that having a specialized nurse or other
healthcare professional follow up each long-term prescrip-
tion with feedback to the patient improves client-
professional relationships.
6 Primary medication nonadherence
Nonadherence has two levels: primary and secondary. We
know very little about primary medication nonadherence in
osteoporosis and are only beginning to understand the
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While early compliance and persistence data were devel-
oped from self-report [12] with the advent of e-prescribing,
prescriptions written can be matched to prescriptions filled
[13].
The first studies collected information using self-report.
Kennedy [12] used data from the 2004 Medicare current
beneficiary survey, an ongoing national panel survey
conducted by the Center for Medicare and Medicaid
Services, to study possible patterns in unfilled Medicare
prescriptions. The sample included 14,464 community-
dwelling Medicare beneficiaries who were asked if there
were any prescriptions they had not filled that were written
or phoned in by their physician. Respondents were asked to
answer about medications in general as they were not asked
the names or types of specific medications. In 2004, an
estimated 1.6 million Medicare beneficiaries or 4.4%
admitted failing to fill or refill at least one prescription.
The most common reasons for not filling these prescrip-
tions included the following: (1) cost (55.5%), (2) lack of
insurance coverage (20.2%), (3) did not believe medicine
was necessary for their condition (18.0%), and (4) feared
medicine contraindications or reactions (11.8%). Rates
were higher in those under 65 than those 65 and older
(10.4% versus 3.3%; P<0.001) and for women than men
(5.0% versus 3.6%; P=0.001), for non-whites and whites
(5.5% versus 4.2%; P=0.010), and for dually eligible
Medicaid beneficiaries than for those not covered by
Medicaid (6.3% versus 4.0%; P=0.001).
Failure to fill rates in this study were significantly higher
amongbeneficiarieswithlowincomes(P<0.001), psychiatric
conditions (P<0.001), arthritis (P<0.001), cardiovascular
disease (P=0.003), emphysema, asthma or chronic obstruc-
tive pulmonary disease (P<0.001). Rates were higher for
those with more self-reported chronic conditions (P<0.001).
Among the prescriptions not filled, CNS agents were the
most frequent identified overall, with nonsteroidals (23.6%),
followed by cardiovascular agents (18.3%), and endocrine
metabolic agents (6.5%). The authors concluded that most
Medicare beneficiaries do fill their prescriptions, though
fulfillment is not 100% (Kennedy [12]).
Fischer [13] recently reported primary medication non-
adherence in 75,589 patients treated in a community-based
e-prescribing initiative. With 195,930 e-prescriptions, 78%
or 151,837 were filled. Of 82,245 e-prescriptions for new
medications, 72% or 58,984 were filled. Primary adherence
rates were higher for prescriptions written by primary care
specialists/especially pediatricians−84%. Patients age 18
and younger filled prescriptions at the highest rate at 87%.
Medication class using multivariate analysis is the strongest
predictor of adherence, and nonadherence was common for
newly prescribed medicines for chronic conditions such as
hypertension (28.4%), hyperlipidemia (28.2%), and diabe-
tes (31.4%). We do not currently have such data about
osteoporosis medications. However, these findings strongly
suggest that in the future, efforts to understand and improve
primary adherence in osteoporosis will most likely be
needed as well.
6.1 What are reasons for poor compliance and persistence?
While earlier research on compliance and persistence with
osteoporosis medications focused primarily on convenience
and dosing interval of oral medications, more recent studies
have looked at the role of choice in poor compliance and
persistence.
As pointed out by the 2002 Harris survey done by the
Boston Consulting Group [14], adherence across multiple
medications may often be intentional or deliberate. Recent-
ly Rees and colleagues [15] studied intentional and
unintentional nonadherence to ocular or hypertensive
treatment in patients with glaucoma. Overall, 59 partic-
ipants (45%) reported some degree of nonadherence, of
which 39 participants (66.1%) reported unintentional non-
adherence. However, 10 (16.9%) reported intentional non-
adherence and 10 (16.9%) reported both. Non-adherers
were significantly younger and less likely to have other
nonocular health conditions or used medicine other than
their eye drops and reported lower belief in the necessary of
eye drops for glaucoma. The degree of unintentional
adherence was associated with lower belief in the necessary
of eye drops while the degree of intentional nonadherence
was associated with concerns about eye drops. The authors
concluded that both intentional and unintentional dimen-
sions are poorly understood and need additional research.
Intentional non-adherers have also been studied using
the necessity concerns framework and beliefs in medicine
questionnaire by Clifford [16]. Intentional non-adherers
compared to adherers have lower perception of the
necessity of new medications and higher level of concerns
about taking them. Adversely, unintentional non-adherers
were not significantly different from adherers. The conclu-
sion is that, when patients start a new medicine for a
chronic condition, intentional non-adherers hold beliefs
significantly different than those of adherers and uninten-
tional non-adherers.
7 Physician and patient attitudes
Additional causes of poor compliance and persistence with
medication may focus on the importance of communication
and physician and patient health beliefs and attitudes. The
patient/physician dyad has been a neglected factor in
explaining why patients may not take their medications
correctly. Patient and physician beliefs about medication
Rev Endocr Metab Disord (2010) 11:275–280 277maybe dissimilar but may also be an important predictor of
patient outcomes. On the other hand, patient and physician
perspectives maybe different. For example, in osteoporosis,
patients are more concerned about potential loss of
independence from fractures, while physicians maybe more
concerned with reducing future fractures.
Christensen [17] studied the extent to which the patient
and provider symmetry in health of locus of control beliefs
was associated with adherence in patients with diabetes and
hypertension. Physician and patient dyads holding similar
beliefs regarding the degree of personal control that the
patients have over health outcomes showed lower diastolic
blood pressure (p=0.02)and greater adherence (p=0.03)
than the dyads in which patients held stronger beliefs in
their own personal control than did their physicians. These
data suggest that attitudinal symmetry and locus of control
may play more important roles in adherence than was
previously thought.
Qualitative interviews with patients in Africa receiving
antiretroviral therapy by Gusdal [18] confirmed that two
important drivers were costs of medications and transpor-
tation to appointments and follow-ups, with a second driver
being personal responsibility for treatment, trust in the
effects of the medications, and trust in the quality of
counseling. The article confirms the importance of health
beliefs.
7.1 Causes of poor compliance and persistence: do race
and ethnicity play a role?
While adherence to medications is suboptimal, what is not
known is whether there are racial and ethnic differences in
adherence. Trinacty [19] studied diabetic medication adher-
ence in African Americans. Black patients are as likely as
whites to initiate oral therapy and fill their first prescription.
They have higher rates of medication discontinuation and
are less adherence over time. These increased over the first
6 months but then stabilized thereafter.
7.2 Causes of poor compliance and persistence: is it
important that osteoporosis is an asymptomatic disease?
The literature has often cited the asymptomatic nature of
osteoporosis until fracture as a major cause of poor
compliance and adherence. However, even in symptomatic
conditions such as diabetes, adherence to oral hypoglyce-
mic therapy ranges from 36% to 93% in patients who had
treatment for 6–24 months. (Cramer [20]) Similar to
diabetes, there is a low rate of treatment adherence to
medication in patients with an inflammatory painful
arthritis such as rheumatoid arthritis with 33–40% of
patients not taking their medications as prescribed (van
den Bemt [21]).
7.3 Causes of poor compliance and persistence: the role
of depression
Issues around poor compliance and persistence in the face
of major depression are doubled because patients must first
be compliant with their medication for depression, some-
thing that is infrequent, especially after psychiatric hospi-
talization (Zivin [22]). The relationship between
osteoporosis and depression is complex, with depression
potentially being both a risk factor and a consequence of
fractures (Cizza [23]). As a result, the impact of depression
on compliance and persistence with osteoporosis medica-
tion is complex as well. In a secondary analysis of data
from the Fracture Intervention Trial (FIT), Buist [24] found
that depression was a significant predictor of early
discontinuation of medication—in this case, alendronate.
Compliance and persistence with osteoporosis medications
in the face of depression is an area that needs additional
research.
7.4 Causes of poor compliance and persistence: the role
of alcohol
In an early study of alcohol consumption and its impact on
compliance with type II diabetes recommendations,
Johnson [25] found that drinkers were significantly less
likely to comply with dietary recommendation (p=0.01),
exercise (p<0.05) oral medication use (p<0.01), and
attending follow-up clinic visits (p<0.05) (Johnson). Some
years later, alcohol misuse as measured by a brief screening
questionnaire was found to be associated with an increased
risk for medication nonadherence to oral antihypertensives
and hyperlipidemic agents but not for oral hypoglycemics.
However, oral hypoglycemic users had a higher proportion
of non-drinkers which may have influenced results (Bryson
[26]).
7.5 Causes of poor compliance and persistence:
what is the role of switching medications?
It is not uncommon for patients on weekly bisphosphonates
to be switched from 1 weekly bisphosphonate or 1 monthly
bisphosphonate to another. Switching is often either based
on insurance coverage or patient intolerability. In a
retrospective data base analysis of pharmacy claims data,
Thiebaud [27] studied a sample of 38,866 new statin users
between the ages of 18 and 65. They found that patients
who were switched to another statin were significantly less
compliant with medication than were those patients who
remained on the same statin (p<0.001); they were also less
persistent by 21–48% (p<0.001) than were non-switchers.
Although no similar study of osteoporosis medications has
been published of which we are aware, no evidence
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an osteoporotic population (Thiebaud [27]).
7.6 How can we improve compliance and persistence?
Haynes [28] published a review in the Cochrane database
on how to enhance medication adherence. They searched
peer-reviewed articles that reported the success of multiple
randomized controlled interventions to improve medication
adherence. The authors noted that 4 out of 10 articles
reporting short-term treatments showed an effect on bone
adherence and at least one clinical outcome. One
intervention reported 1 RCT that significantly improved
patient adherence but did not enhance any clinical
outcomes. For long-term treatment, 36/81 interventions
from 69 RCTs were associated with significant improve-
ment in adherence but only 25 led to improvement in at
least 1 treatment outcome. Almost all of the interventions
that were effective for long-term care were complex and
included combining one or more of the following:
community care, information reminders, self-monitoring,
reinforcement, constant family therapy, psychological
therapy, crisis intervention, manual telephone follow up
and supportive care. Even the most effective interventions
did not lead to large improvements in treatment outcomes
and adherence. For short-term treatments, several quite
simple interventions increased adherence. However, these
interventions were inconsistent, with fewer than half the
studies showing gain.
However, improvement in medication adherence has
been shown in several recent studies. Conn [29] completed
a meta-analysis of randomized controlled trials of older
adults to determine if there were positive changes in their
medication adherence. Their findings were generally
positive, and the interventions most successful when a
moderate proportion of participants were women, on 3–5
drugs, and when they measured pill count adherence. More
specifically, Russell [30] described a clinical nurse special-
ist led intervention with renal transplant patients to improve
adherence with immunosuppressant medications, the num-
ber 1 predictor of poor outcomes including death. Contin-
uous self-improvement feedback, a theory-based systems
approach, plus an objective marker of compliance (elec-
tronic medicine cap) led patients to significantly improve
their adherence.
Unfortunately, staff intensive interventions can be
expensive, so the challenge is to find cost effective ways
to motivate patients both for fulfillment of the initial
prescription and for persistence over time. Schackman
[31] explored the feasibility of using audio computer-
assisted self interview techniques in routine HIV care. The
intervention helped identify patients at risk for poor
adherence but did not improve clinical outcomes
Accommodating patient goals and preferences in shared
decision-making improves adherence and outcomes in
poorly controlled asthma. Using the shared decision making
process with 612 adults with poorly controlled asthma
resulted in significantly better controller adherence (p<
0.0001) as well as significantly better clinical outcomes
(asthma-related quality of life, health care use, rescue
medication use, asthma control, and lung function) (Wilson
[32]). From these data, the authors suggest that shared
decision-making where clinicians and patients negotiate a
treatment regimen that accommodates patient’s goals and
preferences significantly improves adherence and outcomes
in asthma patients. This approach has not been tested with
osteoporosis patients.
8 Conclusions
Although we recognize the importance of compliance and
persistence with osteoporosis medications improving frac-
ture outcomes, we are only beginning to study the multiple
causes of poor compliance and persistence. Until recently,
simple forgetfulness was blamed for poor medication
behavior. Several researchers have shown that forgetfulness
is only one small reason that individuals do not take their
medicines as directed. Intentional choice of noncompliance
and differences between patient and physician attitudes play
larger roles in this potentially harmful patient behavior.
Ultimately, the most effective interventions to change this
behavior will likely be behavioral interventions to improve
compliance and persistence that are cost effective and
scalable.
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